Join
Live feed
·
PRReleasevia Quantisnow
Boston Scientific Corporation logo

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints

ByQuantisnow·Wall Street's wire, on your screen.
BSX· Boston Scientific Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BSX (Boston Scientific Corporation) and more on Quantisnow.